|Bid||0.0000 x 27000|
|Ask||0.0000 x 3200|
|Day's Range||1.6600 - 1.7400|
|52 Week Range||1.6000 - 3.5700|
|Beta (3Y Monthly)||1.53|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Altria Group Inc. (MO), BioMarin Pharmaceutical Inc. (BMRN), Pennant Park Investment Corp. (PNNT), and Rigel Pharmaceuticals Inc. (RIGL) have declined to their three-year lows Continue reading...
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Rigel (RIGL) delivered earnings and revenue surprises of 14.29% and 12.56%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2019 results.
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.
Rigel (RIGL) delivered earnings and revenue surprises of 15.38% and 5.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the South San Francisco, California-based company said it had a loss of 11 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by ...
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shareholders should be happy to see the share price up 16% in the last quarter. But that is minimal compensation for the share price under-performance over the last year. After all...
Raul Rodriguez has been the CEO of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) since 2014. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies ofRead More...
Small-cap biotech Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL )'s shares were advancing Wednesday after it announced an agreement to commercialize fostamatinib, its autoimmune disorder drug. What Happened ...